Last $5.08 USD
Change Today +0.19 / 3.89%
Volume 150.3K
XNPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Snapshot

Open
$4.88
Previous Close
$4.89
Day High
$5.10
Day Low
$4.85
52 Week High
01/13/14 - $7.20
52 Week Low
05/9/14 - $3.15
Market Cap
316.0M
Average Volume 10 Days
234.3K
EPS TTM
$-1.46
Shares Outstanding
62.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENOPORT INC (XNPT)

xenoport inc (XNPT) Related Businessweek News

No Related Businessweek News Found

xenoport inc (XNPT) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders. It markets HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome, as well as for the management of postherpetic neuralgia in adults in the United States. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is being studied in a Phase I clinical trial for the treatment of psoriasis and/or relapsing forms of multiple sclerosis. In addition, it is developing product candidates that have completed Phase II clinical trial, including arbaclofen placarbil, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease. The company has strategic alliance with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

92 Employees
Last Reported Date: 02/28/14
Founded in 1999

xenoport inc (XNPT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $369.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $426.4K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $353.9K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $336.0K
Compensation as of Fiscal Year 2013.

xenoport inc (XNPT) Key Developments

Xenoport, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Xenoport, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues were $5,334,000 compared to $2,086,000 a year ago. Loss from operations was $19,333,000 compared to $24,187,000 a year ago. Net loss was $19,387,000 compared to $24,381,000 a year ago. Basic and diluted net loss per share was $0.31 compared to $0.51 a year ago. For the six months, the company's total revenues were $8,709,000 compared to $2,545,000 a year ago. Loss from operations was $39,816,000 compared to $47,816,000 a year ago. Net loss was $39,935,000 compared to $47,929,000 a year ago. Basic and diluted net loss per share was $0.67 compared to $1.01 a year ago. The increase in revenues in both the second quarter and six months ended June 30, 2014 was principally due to HORIZANT net product sales, which totaled $4.9 million and $7.9 million for the second quarter and six months ended June 30, 2014, respectively.

Xenoport, Inc. to Report Q2, 2014 Results on Aug 06, 2014

Xenoport, Inc. announced that they will report Q2, 2014 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2014

Xenoport, Inc., Q2 2014 Earnings Call, Aug 06, 2014

Xenoport, Inc., Q2 2014 Earnings Call, Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $5.08 USD +0.19

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Access Pharmaceuticals Inc $0.33 USD +0.0061
Biocon Ltd 464.05 INR -6.40
BioDelivery Sciences International Inc $16.00 USD +0.33
Depomed Inc $15.35 USD +0.08
Flamel Technologies SA $15.00 USD +0.30
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.3x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit www.xenoport.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.